Novel Oncogenic Variant in Severe Infantile Myofibromatosis With Response to Imatinib Using Therapeutic Drug Monitoring.
(2022) JCO precision oncology — Vol. 6, n° online, p. e2200250 (2022)
Files
Elsberndetal_manuscript2022.pdf
Accepted manuscript
Open Access - Adobe PDF
- 1.72 MB
Details
- Authors
Elsbernd, Abbey 
Boulouadnine, Boutaina Ahmed, Atif Farooqi, Midhat
- Affiliations
Citations
Elsbernd, A., Boulouadnine, B., Ahmed, A., Farooqi, M., Sandritter, T., Shakhnovich, V., Blanding, D., Demoulin, J. B., & Thompson, J. (2022). Novel Oncogenic Variant in Severe Infantile Myofibromatosis With Response to Imatinib Using Therapeutic Drug Monitoring. JCO precision oncology, 6(online), e2200250. https://doi.org/10.1200/PO.22.00250 (Original work published 2022)